insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration

Group 1: Company Overview - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 11 Defensive Healthcare Dividend Stocks to buy now [1] - The company has a strong financial performance, with at least seven drugs showing double-digit sales increases in Q2 [4] - The stock offers a dividend yield of 5.69%, having raised its dividend for 16 consecutive years [4] Group 2: Research and Development - Bristol-Myers Squibb is collaborating with insitro to advance research on amyotrophic lateral sclerosis (ALS) using AI technology [2] - The partnership will utilize insitro's AI-powered ChemML platform to design medicines targeting a newly identified ALS-related gene [3] - The collaboration may bring up to $20 million in additional funding, with the total partnership value potentially exceeding $2 billion if milestones are met [3]